TCGA-MF-A522-01A-11R-A262-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 54
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.580
- E2F_TARGETS+0.530
- MYC_TARGETS_V1+0.530
- G2M_CHECKPOINT+0.470
- MTORC1_SIGNALING+0.350
- MITOTIC_SPINDLE+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.330
- GLYCOLYSIS+0.300
- OXIDATIVE_PHOSPHORYLATION+0.260
- DNA_REPAIR+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.490
- INTERFERON_GAMMA_RESPONSE-0.460
- INFLAMMATORY_RESPONSE-0.420
- ALLOGRAFT_REJECTION-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- IL6_JAK_STAT3_SIGNALING-0.340
- KRAS_SIGNALING_UP-0.330
- COMPLEMENT-0.310
- IL2_STAT5_SIGNALING-0.240
- ANGIOGENESIS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088859 | — | — | 0.931 |
| 2 | TCGA-58-A46N-01A-11R-A24H-07 | — | cohortSQ2 | 0.927 |
| 3 | C3N-04155 | — | cohortSQ2 | 0.921 |
| 4 | TCGA-LA-A446-01A-21R-A24Z-07 | — | cohortSQ2 | 0.913 |
| 5 | BS_MV6ASWV9 | ATRT | — | 0.912 |
| 6 | TCGA-60-2722-01A-01R-0851-07 | — | cohortSQ2 | 0.910 |
| 7 | TCGA-56-7823-01B-11R-2247-07 | — | cohortSQ2 | 0.909 |
| 8 | ERR2208940 | — | — | 0.904 |
| 9 | TCGA-94-A5I6-01A-21R-A27Q-07 | — | cohortSQ2 | 0.901 |
| 10 | TCGA-XF-A9ST-01A-11R-A42T-07 | — | — | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |